Jiri Bonaventura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiri Bonaventura has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Josef Veselka
Department of Cardiology, 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic
8 shared publicationsBarry J. Maron
Lahey Hosp & Med Ctr, Hypertroph Cardiomyopathy Ctr, Burlington, MA USA
4 shared publications- Martin S. Maron
Lahey Hospital and Medical Center
4 shared publications - Barry J. Maron
HCM Center, Lahey Hospital and Medical Center, Burlington, MA
3 shared publications Ethan J. Rowin
HCM Center, Lahey Hospital and Medical Center, Burlington, Massachusetts
3 shared publications- Ethan J. Rowin
Lahey Hospital and Medical Center
3 shared publications
Latest Publications
- 6 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (14) , 1290-1305
International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy
BACKGROUND: Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. METHODS: Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. RESULTS: A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively. CONCLUSIONS: In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.
- 6 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (14) , 1290-1305
International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy
BACKGROUND: Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. METHODS: Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. RESULTS: A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively. CONCLUSIONS: In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.
- Open Access
PANGENOMES AID ACCURATE DETECTION OF LARGE INSERTION AND DELETIONS FROM GENE PANEL DATA: THE CASE OF CARDIOMYOPATHIES
Gene panels represent a widely used strategy for genetic testing in a vast range of Mendelian disorders. While this approach aids reliable bioinformatic detection of short coding variants, it fails to detect most larger variants. Recent studies have recommended the adoption of pangenomes to augment detection of large variants from targeted sequencing, potentially providing diagnostic laboratories with the possibility to streamline diagnostic work-ups and reduce costs. Here, we analyze a large-scale cohort comprising 1,952 cardiomyopathy cases and 1,805 technically matched controls and show that a pangenome-based workflow, GRAF, conjugates higher precision and recall (F1 score 0.86) compared with conventional orthogonal methods (F1 0-0.57) in detecting potentially pathogenic ≥20bp variants from short-read panel data. Our results indicate that pangenome-based workflows aid precise and cost-effective detection of large variants from targeted sequencing data in the clinical context. This will be particularly relevant for conditions in which these variants explain a high proportion of the disease burden.
Open AccessPANGENOMES AID ACCURATE DETECTION OF LARGE INSERTION AND DELETIONS FROM GENE PANEL DATA: THE CASE OF CARDIOMYOPATHIES
Gene panels represent a widely used strategy for genetic testing in a vast range of Mendelian disorders. While this approach aids reliable bioinformatic detection of short coding variants, it fails to detect most larger variants. Recent studies have recommended the adoption of pangenomes to augment detection of large variants from targeted sequencing, potentially providing diagnostic laboratories with the possibility to streamline diagnostic work-ups and reduce costs. Here, we analyze a large-scale cohort comprising 1,952 cardiomyopathy cases and 1,805 technically matched controls and show that a pangenome-based workflow, GRAF, conjugates higher precision and recall (F1 score 0.86) compared with conventional orthogonal methods (F1 0-0.57) in detecting potentially pathogenic ≥20bp variants from short-read panel data. Our results indicate that pangenome-based workflows aid precise and cost-effective detection of large variants from targeted sequencing data in the clinical context. This will be particularly relevant for conditions in which these variants explain a high proportion of the disease burden.
- 25 July 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 415, 132366
Chasing the molecular background of hypertrophic cardiomyopathy: The continuing saga to predict adverse outcomes with sarcomere mutations
- 25 July 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 415, 132366
Chasing the molecular background of hypertrophic cardiomyopathy: The continuing saga to predict adverse outcomes with sarcomere mutations
- Open Access
- 21 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (10) , e033565
Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy
Background: The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved. Methods and Results: We assessed a large international HCM cohort to define in contemporary terms natural history and clinical consequences of genotype. Consecutive patients (n=1468) with established HCM diagnosis underwent genetic testing. Patients with pathogenic (or likely pathogenic) variants were considered genotype positive (G+; n=312; 21%); those without definite disease‐causing mutations (n=651; 44%) or variants of uncertain significance (n=505; 35%) were considered genotype negative (G−). Patients were followed up for a median of 7.8 years (interquartile range, 3.5–13.4 years); HCM end points were examined by cumulative event incidence. Over follow‐up, 135 (9%) patients died, 33 from a variety of HCM‐related causes. After adjusting for age, all‐cause and HCM‐related mortality did not differ between G− versus G+ patients (hazard ratio [HR], 0.78 [95% CI, 0.46–1.31]; P =0.37; HR, 0.93 [95% CI, 0.38–2.30]; P =0.87, respectively). Adverse event rates, including heart failure progression to class III/IV, heart transplant, or heart failure death, did not differ (G− versus G+) when adjusted for age (HR, 1.20 [95% CI, 0.63–2.26]; P =0.58), nor was genotype independently associated with sudden death event risk (HR, 1.39 [95% CI, 0.88–2.21]; P =0.16). In multivariable analysis, age was the only independent predictor of all‐cause and HCM‐related mortality, heart failure progression, and sudden death events. Conclusions: In this large consecutive cohort of patients with HCM, genotype (G+ or G−) was not a predictor of clinical course, including all‐cause and HCM‐related mortality and risk for heart failure progression or sudden death. G+ status should not be used to dictate clinical management or predict outcome in HCM.
- 21 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (10) , e033565
Open AccessRelationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy
Background: The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved. Methods and Results: We assessed a large international HCM cohort to define in contemporary terms natural history and clinical consequences of genotype. Consecutive patients (n=1468) with established HCM diagnosis underwent genetic testing. Patients with pathogenic (or likely pathogenic) variants were considered genotype positive (G+; n=312; 21%); those without definite disease‐causing mutations (n=651; 44%) or variants of uncertain significance (n=505; 35%) were considered genotype negative (G−). Patients were followed up for a median of 7.8 years (interquartile range, 3.5–13.4 years); HCM end points were examined by cumulative event incidence. Over follow‐up, 135 (9%) patients died, 33 from a variety of HCM‐related causes. After adjusting for age, all‐cause and HCM‐related mortality did not differ between G− versus G+ patients (hazard ratio [HR], 0.78 [95% CI, 0.46–1.31]; P =0.37; HR, 0.93 [95% CI, 0.38–2.30]; P =0.87, respectively). Adverse event rates, including heart failure progression to class III/IV, heart transplant, or heart failure death, did not differ (G− versus G+) when adjusted for age (HR, 1.20 [95% CI, 0.63–2.26]; P =0.58), nor was genotype independently associated with sudden death event risk (HR, 1.39 [95% CI, 0.88–2.21]; P =0.16). In multivariable analysis, age was the only independent predictor of all‐cause and HCM‐related mortality, heart failure progression, and sudden death events. Conclusions: In this large consecutive cohort of patients with HCM, genotype (G+ or G−) was not a predictor of clinical course, including all‐cause and HCM‐related mortality and risk for heart failure progression or sudden death. G+ status should not be used to dictate clinical management or predict outcome in HCM.
- Open Access
- 6 May 2024
- Published by Solen s.r.o. in Vnitrni Lekarstvi
- Vol. 70 (3) , 198-206
News in cardiology 2023
?l?nek shrnuje novinky v kardiologii v roce 2023, kter? maj? dopady pro klinickou praxi nejen kardiolog? a internist?, ale i diabetolog?, praktick?ch l?ka?? a dal??ch specializac?. V ?vodn? ??sti jsou diskutov?na aktu?ln? doporu?en? vydan? Evr... ?l?nek shrnuje novinky v kardiologii v roce 2023, kter? maj? dopady pro klinickou praxi nejen kardiolog? a internist?, ale i diabetolog?, praktick?ch l?ka?? a dal??ch specializac?. V ?vodn? ??sti jsou diskutov?na aktu?ln? doporu?en? vydan? Evr...
- 6 May 2024
- Published by Solen s.r.o. in Vnitrni Lekarstvi
- Vol. 70 (3) , 198-206
Open AccessNews in cardiology 2023
?l?nek shrnuje novinky v kardiologii v roce 2023, kter? maj? dopady pro klinickou praxi nejen kardiolog? a internist?, ale i diabetolog?, praktick?ch l?ka?? a dal??ch specializac?. V ?vodn? ??sti jsou diskutov?na aktu?ln? doporu?en? vydan? Evr... ?l?nek shrnuje novinky v kardiologii v roce 2023, kter? maj? dopady pro klinickou praxi nejen kardiolog? a internist?, ale i diabetolog?, praktick?ch l?ka?? a dal??ch specializac?. V ?vodn? ??sti jsou diskutov?na aktu?ln? doporu?en? vydan? Evr...
- Open Access
- 1 September 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 7 (9) , ytad462
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy and bilateral lung transplantation for idiopathic pulmonary fibrosis: a case report
Background: We present an uncommon case of a patient with hypertrophic obstructive cardiomyopathy and idiopathic pulmonary fibrosis. The case demonstrates the importance of pre-transplant cardiology workup and the need of interdisciplinary approach in diagnosing the cause of dyspnoea. Case summary: The 52-year-old male patient was diagnosed with idiopathic pulmonary fibrosis in 2019 and gradually became oxygen dependent due to progression of dyspnoea. Bilateral lung transplantation was recommended in 2021. During pre-transplant cardiology workup, the patient was diagnosed with hypertrophic cardiomyopathy with left ventricular outflow tract (LVOT) obstruction. Considering the high surgical risk of the patient, alcohol septal ablation was performed with subsequent decrease of LVOT gradient. Bilateral lung transplantation was successfully performed afterwards. The patient’s symptoms improved to NYHA class II at one year follow-up. Discussion: We present a rare case of combined cause of dyspnoea—coexistence of hypertrophic obstructive cardiomyopathy and idiopathic pulmonary fibrosis in one patient. Due to high surgical risk, the patient underwent alcohol septal ablation with successful elimination of LVOT gradient and subsequently bilateral lung transplantation.
- 1 September 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 7 (9) , ytad462
Open AccessAlcohol septal ablation for hypertrophic obstructive cardiomyopathy and bilateral lung transplantation for idiopathic pulmonary fibrosis: a case report
Background: We present an uncommon case of a patient with hypertrophic obstructive cardiomyopathy and idiopathic pulmonary fibrosis. The case demonstrates the importance of pre-transplant cardiology workup and the need of interdisciplinary approach in diagnosing the cause of dyspnoea. Case summary: The 52-year-old male patient was diagnosed with idiopathic pulmonary fibrosis in 2019 and gradually became oxygen dependent due to progression of dyspnoea. Bilateral lung transplantation was recommended in 2021. During pre-transplant cardiology workup, the patient was diagnosed with hypertrophic cardiomyopathy with left ventricular outflow tract (LVOT) obstruction. Considering the high surgical risk of the patient, alcohol septal ablation was performed with subsequent decrease of LVOT gradient. Bilateral lung transplantation was successfully performed afterwards. The patient’s symptoms improved to NYHA class II at one year follow-up. Discussion: We present a rare case of combined cause of dyspnoea—coexistence of hypertrophic obstructive cardiomyopathy and idiopathic pulmonary fibrosis in one patient. Due to high surgical risk, the patient underwent alcohol septal ablation with successful elimination of LVOT gradient and subsequently bilateral lung transplantation.
- 30 June 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 200, 236-238
Do Implantable Cardioverter-Defibrillators Really Belong on the Athlete Field?
- 30 June 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 200, 236-238
Do Implantable Cardioverter-Defibrillators Really Belong on the Athlete Field?
- Open Access
- 20 June 2023
- Published by Elsevier in Heart Rhythm O2
- Vol. 4 (8) , 506-516
Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity
- 20 June 2023
- Published by Elsevier in Heart Rhythm O2
- Vol. 4 (8) , 506-516
Open AccessAnalysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity
- Open Access
- 20 June 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (12) , e028974
Is Hypertrophic Cardiomyopathy Always a Familial and Inherited Disease?
- 20 June 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (12) , e028974
Open AccessIs Hypertrophic Cardiomyopathy Always a Familial and Inherited Disease?
- 8 December 2022
- Published by Elsevier in The American Journal of Medicine
- Vol. 136 (3) , 315-321
Risks of the Athletic Field Revisited: Report of Unusual Occurrences of Cardiac Arrest and Sudden Death in Professional Soccer Players
- 8 December 2022
- Published by Elsevier in The American Journal of Medicine
- Vol. 136 (3) , 315-321
Risks of the Athletic Field Revisited: Report of Unusual Occurrences of Cardiac Arrest and Sudden Death in Professional Soccer Players